Prevalence of Diabetes and Cardiovascular Risk in the Middle East and Africa: Primary Results of the PACT-MEA Study

Affiliations

• ¹ St. Michael's Hospital, University of Toronto, Ontario, Canada (S.V.).
• ² Royal College of Surgeons in Ireland-Bahrain, King Hamad University Hospital, Adilya, Bahrain (N.A.).
• ³ Endocrine Department, Dubai Hospital, Dubai Health Authority, United Arab Emirates (F.A.).
• ⁴ Department of Pediatrics, Farwaniya Hospital, Kuwait City, Kuwait (H.A.).
• ⁵ Department of Population Health, Dasman Diabetes Institute, Kuwait City, Kuwait (H.A.).
• ⁶ Heart, Vascular & Thoracic Institute at Cleveland Clinic Abu Dhabi, United Arab Emirates (W.A., H.S.).
• ⁷ Unit of Diabetes, Lipidology & Metabolism; Department of Internal Medicine/Alexandria Faculty of Medicine, Alexandria University, Egypt (S.H.A.-K.).
• ⁸ Endocrinology Section, Bader Medical Complex, Amman, Jordan (J.H.).
• ⁹ Novo Nordisk A/S, Søborg, Denmark (L.L.N.H., E.M.C., G.T.).
• ¹⁰ Cape Town Medical Research Centre, Cape Town, South Africa (L.L.).
• ¹¹ Department of Medicine, Weill Cornell Medicine-Qatar, Education City, Doha, Qatar (R.A.M.).
• ¹² Novo Nordisk Saglik Urunleri Tic Ltd Sti, Istanbul, Turkey (G.Y.).
• ¹³ School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom (S.S.).
• ¹⁴ Institute of Medicines Development, Cardiff, United Kingdom (S.S.).